Agonist and antimineralocorticoid activities of spirolactones.
To investigate the mechanism of action of antimineralocorticoids, a series of spirolactone analogues was evaluated for both mineralocorticoid antagonist and agonist activity. Antagonist activity was assessed by inhibition of aldosterone stimulated sodium transport employing toad bladder short-circuit current (SCC) measurements. Agonist activity was assessed in the same system by the direct effect of spirolactones on SCC. Opening of the gamma-lactone ring of a spirolactone dramatically decreased antagonist activity in the compound studied. Several C-7 chi-substitutions resulted in either enhanced or diminished activity, whereas deletion of the C-10 methyl group (i.e., 19-nor compound) had only minimal effects on antagonist potency. Agonist activity was demonstrable for three of the analogues studied: the 19-nor compound, and those containing a C-7 chi-substitution with a carboxyl isopropyl ester or a C-6-7 cyclopropyl linkage. The functional activity in toad bladder was compared to previous measurements of the relative binding affinity of the same spirolactones for mineralocorticoid receptors in rat kidney. Although there was some correlation between binding to rat kidney receptors and antagonist activity in the toad bladder, the results did not coincide in the case of the three spirolactones that possessed partial agonist activity. Some of the discrepancy may have resulted from differences between mammalian and amphibian receptors; however, intrinsic agonist activity limits antagonist potency and thus may cause a divergence between binding and functional studies limited to antagonist activity alone. Binding affinity, although indicative of total activity, fails to distinguish agonist from antagonist potency.
D000450:Aldosterone / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D001693:Biological Transport, Active; D002024:Bufo marinus; D000451:Mineralocorticoid Receptor Antagonists; D011956:Receptors, Cell Surface; D012964:Sodium / Q000378:metabolism; D013148:Spironolactone / Q000494:pharmacology*; D001743:Urinary Bladder / Q000378:metabolism
D000451:Mineralocorticoid Receptor Antagonists; D011956:Receptors, Cell Surface; D013148:Spironolactone; D000450:Aldosterone; D012964:Sodium